FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083776688> ?p ?o ?g. }

• W3083776688 endingPage "1778" @default.
• W3083776688 startingPage "1778" @default.
• W3083776688 abstract "Anthracycline-based therapy is standard first-line treatment for most patients with advanced and metastatic sarcomas. Although multiple trials have attempted to show improved outcomes in patients with soft-tissue sarcoma over doxorubicin monotherapy, each has fallen short of demonstrating improved outcomes.To evaluate the safety and efficacy of doxorubicin in combination with pembrolizumab in patients with advanced, anthracycline-naive sarcomas.This nonrandomized clinical trial used a 2-stage phase 2 design and was performed at a single, academic sarcoma specialty center. Patients were adults with good performance status and end-organ function. Patients with all sarcoma subtypes were allowed to enroll with the exception of osteosarcoma, Ewing sarcoma, and alveolar and embryonal rhabdomyosarcoma.Two dose levels of doxorubicin (45 and 75 mg/m2) were tested for safety in combination with pembrolizumab.Objective response rate (ORR) was the primary end point. Overall survival (OS) and progression-free survival (PFS) were secondary end points. Correlative studies included immunohistochemistry, gene expression, and serum cytokines.A total of 37 patients (22 men; 15 women) were treated in the combined phase 1/2 trial. The median (range) patient age was 58.4 (25-80) years. The most common histologic subtype was leiomyosarcoma (11 patients). Doxorubicin plus pembrolizumab was well tolerated without significant unexpected toxic effects. The ORR was 13% for phase 2 patients and 19% overall. Median PFS was 8.1 (95% CI, 7.6-10.8) months. Median OS was 27.6 (95% CI, 18.7-not reached) months at the time of this analysis. Two of 3 patients with undifferentiated pleomorphic sarcoma and 2 of 4 patients with dedifferentiated liposarcoma had durable partial responses. Tumor-infiltrating lymphocytes were present in 21% of evaluable tumors and associated with inferior PFS (log-rank P = .03). No dose-limiting toxic effects were observed.In this nonrandomized clinical trial, doxorubicin plus pembrolizumab was well tolerated. Although the primary end point for ORR was not reached, the PFS and OS observed compared favorably with prior published studies. Further studies are warranted, especially those focusing on undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.ClinicalTrials.gov Identifier: NCT02888665." @default.
• W3083776688 created "2020-09-14" @default.
• W3083776688 creator A5006022670 @default.
• W3083776688 creator A5009715770 @default.
• W3083776688 creator A5013176389 @default.
• W3083776688 creator A5015483526 @default.
• W3083776688 creator A5023928127 @default.
• W3083776688 creator A5026451121 @default.
• W3083776688 creator A5033280951 @default.
• W3083776688 creator A5041041464 @default.
• W3083776688 creator A5044957412 @default.
• W3083776688 creator A5045944321 @default.
• W3083776688 creator A5048969933 @default.
• W3083776688 creator A5049572188 @default.
• W3083776688 creator A5053414263 @default.
• W3083776688 creator A5058943490 @default.
• W3083776688 creator A5081314903 @default.
• W3083776688 creator A5086593114 @default.
• W3083776688 date "2020-11-01" @default.
• W3083776688 modified "2023-10-16" @default.
• W3083776688 title "Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma" @default.
• W3083776688 cites W2019607817 @default.
• W3083776688 cites W2081070412 @default.
• W3083776688 cites W2136344041 @default.
• W3083776688 cites W2413552560 @default.
• W3083776688 cites W2520149112 @default.
• W3083776688 cites W2653632515 @default.
• W3083776688 cites W2730021240 @default.
• W3083776688 cites W2752560124 @default.
• W3083776688 cites W2762797139 @default.
• W3083776688 cites W2771691472 @default.
• W3083776688 cites W2944423827 @default.
• W3083776688 cites W3001836957 @default.
• W3083776688 cites W3014683777 @default.
• W3083776688 cites W4231960742 @default.
• W3083776688 doi "https://doi.org/10.1001/jamaoncol.2020.3689" @default.
• W3083776688 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7489365" @default.
• W3083776688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32910151" @default.
• W3083776688 hasPublicationYear "2020" @default.
• W3083776688 type Work @default.
• W3083776688 sameAs 3083776688 @default.
• W3083776688 citedByCount "58" @default.
• W3083776688 countsByYear W30837766882021 @default.
• W3083776688 countsByYear W30837766882022 @default.
• W3083776688 countsByYear W30837766882023 @default.
• W3083776688 crossrefType "journal-article" @default.
• W3083776688 hasAuthorship W3083776688A5006022670 @default.
• W3083776688 hasAuthorship W3083776688A5009715770 @default.
• W3083776688 hasAuthorship W3083776688A5013176389 @default.
• W3083776688 hasAuthorship W3083776688A5015483526 @default.
• W3083776688 hasAuthorship W3083776688A5023928127 @default.
• W3083776688 hasAuthorship W3083776688A5026451121 @default.
• W3083776688 hasAuthorship W3083776688A5033280951 @default.
• W3083776688 hasAuthorship W3083776688A5041041464 @default.
• W3083776688 hasAuthorship W3083776688A5044957412 @default.
• W3083776688 hasAuthorship W3083776688A5045944321 @default.
• W3083776688 hasAuthorship W3083776688A5048969933 @default.
• W3083776688 hasAuthorship W3083776688A5049572188 @default.
• W3083776688 hasAuthorship W3083776688A5053414263 @default.
• W3083776688 hasAuthorship W3083776688A5058943490 @default.
• W3083776688 hasAuthorship W3083776688A5081314903 @default.
• W3083776688 hasAuthorship W3083776688A5086593114 @default.
• W3083776688 hasBestOaLocation W30837766881 @default.
• W3083776688 hasConcept C121608353 @default.
• W3083776688 hasConcept C126322002 @default.
• W3083776688 hasConcept C141071460 @default.
• W3083776688 hasConcept C142724271 @default.
• W3083776688 hasConcept C143998085 @default.
• W3083776688 hasConcept C203092338 @default.
• W3083776688 hasConcept C2776694085 @default.
• W3083776688 hasConcept C2776802502 @default.
• W3083776688 hasConcept C2777532014 @default.
• W3083776688 hasConcept C2777701055 @default.
• W3083776688 hasConcept C2778256501 @default.
• W3083776688 hasConcept C2778629024 @default.
• W3083776688 hasConcept C2780057760 @default.
• W3083776688 hasConcept C2780844630 @default.
• W3083776688 hasConcept C2781303535 @default.
• W3083776688 hasConcept C530470458 @default.
• W3083776688 hasConcept C535046627 @default.
• W3083776688 hasConcept C71924100 @default.
• W3083776688 hasConceptScore W3083776688C121608353 @default.
• W3083776688 hasConceptScore W3083776688C126322002 @default.
• W3083776688 hasConceptScore W3083776688C141071460 @default.
• W3083776688 hasConceptScore W3083776688C142724271 @default.
• W3083776688 hasConceptScore W3083776688C143998085 @default.
• W3083776688 hasConceptScore W3083776688C203092338 @default.
• W3083776688 hasConceptScore W3083776688C2776694085 @default.
• W3083776688 hasConceptScore W3083776688C2776802502 @default.
• W3083776688 hasConceptScore W3083776688C2777532014 @default.
• W3083776688 hasConceptScore W3083776688C2777701055 @default.
• W3083776688 hasConceptScore W3083776688C2778256501 @default.
• W3083776688 hasConceptScore W3083776688C2778629024 @default.
• W3083776688 hasConceptScore W3083776688C2780057760 @default.
• W3083776688 hasConceptScore W3083776688C2780844630 @default.
• W3083776688 hasConceptScore W3083776688C2781303535 @default.
• W3083776688 hasConceptScore W3083776688C530470458 @default.
• W3083776688 hasConceptScore W3083776688C535046627 @default.

• next